1/13
Looks like no tags are added yet.
Primary nephron site of action for potassium-sparing diuretics
Collecting duct renal tubules and late distal tubule
Mechanism of action of spironolactone
Aldosterone antagonist that blocks aldosterone receptors to promote sodium and water excretion while retaining potassium
Primary hormone targeted and inhibited by potassium-sparing diuretics
Aldosterone (a mineralocorticoid hormone)
Diuretic potency of potassium-sparing diuretics relative to loop and thiazide diuretics
Weaker and less effective when used as monotherapy
Serum potassium threshold indicating discontinuation of a potassium-sparing diuretic
>5.0mEq/L
Approximate onset time for spironolactone to demonstrate therapeutic effects
About 48hours
Three potassium-sparing diuretics other than spironolactone
Amiloride, triamterene, and eplerenone
Potassium-sparing diuretic noted for reducing myocardial fibrosis in cardiac patients
Spironolactone
Antihypertensive drug classes contraindicated for concurrent use with potassium-sparing diuretics
ACE inhibitors and angiotensin II receptor blockers (ARBs)
Guideline on using potassium supplements alongside potassium-sparing diuretics
Contraindicated due to the risk of severe hyperkalemia
Common formulation strategy for potassium-sparing diuretics to enhance diuresis and maintain electrolyte balance
Combined in a single pill with a potassium-wasting diuretic (primarily hydrochlorothiazide)
Three common combination formulations containing both a potassium-sparing and a potassium-wasting diuretic
Spironolactone-HCTZ, amiloride-HCTZ, and triamterene-HCTZ
Potassium-sparing diuretics effective as standalone antihypertensive agents
Amiloride and eplerenone
Clinical indications for triamterene therapy
Edema associated with heart failure (HF) or cirrhosis of the liver